By Christopher Anderson, Alexis Miller Faculty Mentor: Dr. Parrish Waters Abstract Semaglutide (marketed as Ozempic, Wegovy, et al.) is an agonist of the glucagon-like peptide-1 receptor (GLP-1-R) that enjoys a high use rate for both its on-label (therapy for diabetes mellitus) and off-label (appetite quenching) effects. Semaglutide also has positive effects on cognitive performance, although…